|
COPYRIGHT 2006 International Medical News Group
NICE, FRANCE -- Two different rifabutin-based, triple-therapy approaches proved to be safe and effective rescue therapies in two European trials involving patients with treatment-resistant Helicobacter pylori.
In primary care, first-line triple therapy has been shown to fail in up to 27% of patients. These failures are frequently due to metronidazole or clarithromycin resistance. Further, up to 75% of these infections are resistant to both drugs, Dr. Stephan Miehlke said at the 16th European Congress of Clinical Microbiology and Infectious Diseases.
Triple therapy with a proton pump inhibitor, rifabutin, and either amoxicillin or levofloxacin has...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
